
McKesson Corporation (MCK)
$
820.25
+9.69 (1.18%)
Key metrics
Financial statements
Free cash flow per share
45.9888
Market cap
102.5 Billion
Price to sales ratio
0.2715
Debt to equity
-5.0498
Current ratio
0.8829
Income quality
1.9809
Average inventory
24 Billion
ROE
-1.2479
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
McKesson Corporation, founded in 1833 and headquartered in Irving, Texas, provides a wide range of healthcare services both in the United States and internationally. The company operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment is involved in the distribution of branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, along with other healthcare-related products. Additionally, this segment offers practice management, technology, clinical support, and business solutions tailored for community-based oncology and other specialty practices. It also provides consulting, outsourcing, technological, and various services while selling financial, operational, and clinical solutions to pharmacies. The International segment serves wholesale, institutional, and retail customers across 13 European countries and Canada. The Medical-Surgical Solutions segment focuses on distributing medical-surgical supplies, logistics, and other essential services to healthcare providers. Meanwhile, the RxTS segment caters to biopharma and life sciences partners, addressing medication challenges throughout patient journeys; it connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions while also providing third-party logistics and wholesale distribution support solutions. The company reported depreciation and amortization expenses of $636,000,000.00 reflecting the wear and tear of its assets. Its selling, general, and administrative expenses total $8,022,000,000.00 indicating operational overhead costs. The interest income earned amounting to $173,000,000.00 showcases its financial investments. Overall, the total costs and expenses for the company are $354,679,000,000.00 reflecting comprehensive spending, while the EBITDA stands at $5,251,000,000.00 a key indicator of the company's operational profitability. In the financial marketplace, the stock is priced at $698.31 positioning it in the higher-end market. It has an average trading volume of 761,861.00 indicating moderate liquidity in its trading activities. With a significant market capitalization of $102,531,245,899.00 McKesson Corporation establishes itself as a dominant player in the healthcare industry. The company is an essential participant in the Medical - Distribution industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its domain.
Investing in McKesson Corporation (MCK) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict McKesson Corporation stock to fluctuate between $565.75 (low) and $895.58 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-12-19, McKesson Corporation's market cap is $102,531,245,899, based on 124,999,995 outstanding shares.
Compared to Eli Lilly & Co., McKesson Corporation has a Lower Market-Cap, indicating a difference in performance.
McKesson Corporation pays dividends. The current dividend yield is 0.36%, with a payout of $0.82 per share.
To buy McKesson Corporation (MCK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MCK. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
McKesson Corporation's last stock split was 2:1 on 1998-01-05.
Revenue: $359,051,000,000 | EPS: $25.86 | Growth: 14.73%.
Visit https://www.mckesson.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $895.58 (2025-11-26) | All-time low: $192.38 (2021-08-10).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com
McKesson (MCK) reached $823.01 at the closing of the latest trading day, reflecting a +1.13% change compared to its last close.

zacks.com
McKesson (MCK) reported earnings 30 days ago. What's next for the stock?

seekingalpha.com
McKesson Corporation (MCK) Presents at Evercore 8th Annual Healthcare Conference Transcript

zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.

zacks.com
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

seekingalpha.com
McKesson Corporation ( MCK ) UBS Global Healthcare Conference 2025 November 10, 2025 9:30 AM EST Company Participants Britt Vitalone - Executive VP & CFO Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Presentation Kevin Caliendo UBS Investment Bank, Research Division Good morning, everybody. Thank you for coming to the UBS Healthcare Conference.
See all news